货号 | MAB10701-SP |
别名 | APC1 protein; Cachectin; Cachetin; DIF; TNF; TNF, monocyte-derived; tnfa; tnf-a; TNF-alphacachectin; TNFATNF, macrophage-derived; TNFSF1A; TNFSF2; TNFSF2TNF superfamily, member 2; tumor necrosis factor (TNF superfamily, member 2); tumor necrosis factor alpha; Tumor necrosis factor ligand superfamily member 2; tumor necrosis factor; tumor necrosis factor-alpha | 全称 | Tumor Necrosis Factor alpha |
反应种属 | Rhesus Macaque |
应用 | Neutralization |
目标/特异性 | Detects rhesus macaque TNF-alpha in direct ELISAs and Western blots. In direct ELISAs, 10‑25% cross‑reactivity with recombinant human (rh) TNF-alpha and recombinant porcine TNF-alpha is observed and no cross-reactivity with rhEDA-A2, recombinant mouse (rm) EDA, rhAPRIL, rhBAFF, rhFas L, rhGITR L, rhLIGHT, rhLymphotoxin alpha 1 beta 2, rhLymphotoxin alpha 2 beta 1, rhOX40 L, recombinant cotton rat TNF-alpha, rmTNF-alpha, recombinant rat TNF-alpha, rhTRAIL, rhTRANCE, and rhTWEAK is observed. |
使用方法 | Neutralization: Measured by its ability to neutralize TNF‑ alpha -induced cytotoxicity in the L‑929 mouse fibroblast cell line. Matthews, N. and M. L. Neale (1987) in Lymphokines and Interferons, A Practical Approach. Clemens, M. J. et al. (eds): IRL Press. 221. The Neutralization Dose (ND50) is typically 0.2-0.8 µg/mL in the presence of 1 ng/mL Recombinant Rhesus Macaque TNF‑ alpha and 1 µg/mL actinomycin D. |
来源 | Monoclonal Rat IgG1 Clone # 182309 |
产品组分 |
供应商 | R&D Systems |
Entrez Gene IDs | 7124 (Human); 21926 (Mouse); 24835 (Rat); 397086 (Porcine); 280943 (Bovine); 403922 (Canine); 100033834 (Equine); 493755 (Feline); 100009088 (Rabbit) |
纯化方式 | Protein A or G purified from hybridoma culture supernatant |
免疫原 | E. coli-derived recombinant rhesus macaque TNF-alpha Val77-Leu233 Accession # P48094 |
内毒素水平 | <0.10 EU per 1 μg of the antibody by the LAL method. |
生物活性 | Rhesus Macaque |
标记 | Unconjugated |
溶解方法 | Reconstitute at 0.5 mg/mL in sterile PBS. |
背景 | Tumor necrosis factor alpha (TNF-alpha ), also known as cachectin and TNFSF2, is the prototypic ligand of the TNF superfamily. It is a pleiotropic molecule that plays a central role in inflammation, apoptosis, and immune system development. TNF-alpha is produced by a wide variety of immune and epithelial cell types (1, 2). Rhesus TNF-alpha consisits of a 35 amino acid (aa) cytoplasmic domain, a 21 aa transmembrane segment, and a 177 aa extracellular domain (ECD) (3). Within the ECD, rhesus TNF-alpha shares 97% aa sequence identity with human and 71%‑92% with bovine, canine, cotton rat, equine, feline, mouse, porcine, and rat TNF-alpha. The 26 kDa type 2 transmembrane protein is assembled intracellularly to form a noncovalently linked homotrimer (4). Ligation of this complex induces reverse signaling that promotes lymphocyte costimulation but diminishes monocyte responsiveness (5). Cleavage of membrane bound TNF-alpha by TACE/ADAM17 releases a 55 kDa soluble trimeric form of TNF-alpha (6, 7). TNF-alpha trimers bind the ubiquitous TNF RI and the hematopoietic cell-restricted TNF RII, both of which are also expressed as homotrimers (1, 8). TNF-alpha regulates lymphoid tissue development through control of apoptosis (2). It also promotes inflammatory responses by inducing the activation of vascular endothelial cells and macrophages (2). TNF-alpha is a key cytokine in the development of several inflammatory disorders (9). It contributes to the development of type 2 diabetes through its effects on insulin resistance and fatty acid metabolism (10, 11). |
运输条件 | Blue Ice |
存放说明 | 4℃ |
参考文献 |
|
Cytotoxicity Induced by TNF‑ alpha and Neutralization by Rhesus Macaque TNF‑ alpha Antibody. Recombinant Rhesus Macaque TNF‑ alpha (Catalog # 1070-RM) induces cytotoxicity in the the L‑929 mouse fibroblast cell line in a dose-dependent manner (orange line), as measured by crystal violet staining. Cytotoxicity elicited by Recombinant Rhesus Macaque TNF‑ alpha (1 ng/mL) is neutralized (green line) by increasing concentrations of Rat Anti-Rhesus Macaque TNF‑ alpha Monoclonal Antibody (Catalog # MAB10701). The ND50 is typically 0.2‑0.8 µg/mL in the presence of the metabolic inhibitor actinomycin D (1 µg/mL). |